| 1 |
Toledo RA, Jimenez C, Armaiz-Pena G, Arenillas C, Capdevila J, Dahia PLM. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia. Endocr Rev 2023;44:312-22. [PMID: 36301191 DOI: 10.1210/endrev/bnac025] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 2 |
Yfantis A, Mylonis I, Chachami G, Nikolaidis M, Amoutzias GD, Paraskeva E, Simos G. Transcriptional Response to Hypoxia: The Role of HIF-1-Associated Co-Regulators. Cells 2023;12. [PMID: 36899934 DOI: 10.3390/cells12050798] [Reference Citation Analysis]
|
| 3 |
Storey JM, Li Z, Storey KB. Hypoxia inducible factor-1α responds to freezing, anoxia and dehydration stresses in a freeze-tolerant frog. Cryobiology 2023;110:79-85. [PMID: 36442660 DOI: 10.1016/j.cryobiol.2022.11.242] [Reference Citation Analysis]
|
| 4 |
Cammalleri M, Amato R, Dal Monte M, Filippi L, Bagnoli P. The β3 adrenoceptor in proliferative retinopathies: "Cinderella" steps out of its family shadow. Pharmacol Res 2023;190:106713. [PMID: 36863427 DOI: 10.1016/j.phrs.2023.106713] [Reference Citation Analysis]
|
| 5 |
Osaki T, Sunden Y, Warita K, Okamoto Y. Comparison of Characterization in Two-Dimensional and Three-Dimensional Canine Mammary Gland Tumor Cell Models. Yonago Acta Med 2023;66:7-18. [PMID: 36811028 DOI: 10.33160/yam.2023.02.002] [Reference Citation Analysis]
|
| 6 |
Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 2023;8:70. [PMID: 36797231 DOI: 10.1038/s41392-023-01332-8] [Reference Citation Analysis]
|
| 7 |
Stepanovska Tanturovska B, Manaila R, Fabbro D, Huwiler A. Lipids as Targets for Renal Cell Carcinoma Therapy. Int J Mol Sci 2023;24. [PMID: 36834678 DOI: 10.3390/ijms24043272] [Reference Citation Analysis]
|
| 8 |
Melaiu O, Vanni G, Portarena I, Pistolese CA, Anemona L, Pomella S, Bei R, Buonomo OC, Roselli M, Mauriello A, Barillari G. The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. Int J Mol Sci 2023;24. [PMID: 36834641 DOI: 10.3390/ijms24043226] [Reference Citation Analysis]
|
| 9 |
Sawicki KT, De Jesus A, Ardehali H. Iron Metabolism in Cardiovascular Disease: Physiology, Mechanisms, and Therapeutic Targets. Circ Res 2023;132:379-96. [PMID: 36730380 DOI: 10.1161/CIRCRESAHA.122.321667] [Reference Citation Analysis]
|
| 10 |
Nushtaeva A, Ermakov M, Abdurakhmanova M, Troitskaya O, Belovezhets T, Varlamov M, Gayner T, Richter V, Koval O. "Pulsed Hypoxia" Gradually Reprograms Breast Cancer Fibroblasts into Pro-Tumorigenic Cells via Mesenchymal-Epithelial Transition. Int J Mol Sci 2023;24. [PMID: 36768815 DOI: 10.3390/ijms24032494] [Reference Citation Analysis]
|
| 11 |
Liu S, Li Y, Yuan M, Song Q, Liu M. Correlation between the Warburg effect and progression of triple-negative breast cancer. Front Oncol 2022;12:1060495. [PMID: 36776368 DOI: 10.3389/fonc.2022.1060495] [Reference Citation Analysis]
|
| 12 |
Liu CL, Cheng SP, Huang WC, Chen MJ, Lin CH, Chen SN, Chang YC. Aberrant Expression of Solute Carrier Family 35 Member A2 Correlates With Tumor Progression in Breast Cancer. In Vivo 2023;37:262-9. [PMID: 36593004 DOI: 10.21873/invivo.13076] [Reference Citation Analysis]
|
| 13 |
Fu Y, Mackowiak B, Feng D, Lu H, Guan Y, Lehner T, Pan H, Wang XW, He Y, Gao B. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression. Gut 2023:gutjnl-2022-327924. [PMID: 36593103 DOI: 10.1136/gutjnl-2022-327924] [Reference Citation Analysis]
|
| 14 |
Sieow JL, Penny HL, Gun SY, Tan LQ, Duan K, Yeong JPS, Pang A, Lim D, Toh HC, Lim TKH, Engleman E, Rotzschke O, Ng LG, Chen J, Tan SM, Wong SC. Conditional Knockout of Hypoxia-Inducible Factor 1-Alpha in Tumor-Infiltrating Neutrophils Protects against Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2023;24. [PMID: 36614196 DOI: 10.3390/ijms24010753] [Reference Citation Analysis]
|
| 15 |
Dey S, Murmu N, Mondal T, Saha I, Chatterjee S, Manna R, Haldar S, Dash SK, Sarkar TR, Giri B. Multifaceted entrancing role of glucose and its analogue, 2-deoxy-D-glucose in cancer cell proliferation, inflammation, and virus infection. Biomedicine & Pharmacotherapy 2022;156:113801. [DOI: 10.1016/j.biopha.2022.113801] [Reference Citation Analysis]
|
| 16 |
Locatelli F, Minutolo R, De Nicola L, Del Vecchio L. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors. Drugs 2022. [PMID: 36350500 DOI: 10.1007/s40265-022-01783-3] [Reference Citation Analysis]
|
| 17 |
Kocemba-pilarczyk KA, Leskiewicz K, Trojan S, Piwowar M. Looking for hypoxia-fingerprint in multiple myeloma and malignant melanoma patients' transcriptomic data using a binominal distribution model.. [DOI: 10.21203/rs.3.rs-2171664/v1] [Reference Citation Analysis]
|
| 18 |
Yang D, Strobel TD, Bulkescher J, Tessmer C, Hofmann I, Hoppe-Seyler F, Hoppe-Seyler K. FAM57A (Family with Sequence Similarity 57 Member A) Is a Cell-Density-Regulated Protein and Promotes the Proliferation and Migration of Cervical Cancer Cells. Cells 2022;11:3309. [PMID: 36291175 DOI: 10.3390/cells11203309] [Reference Citation Analysis]
|
| 19 |
Taghizadeh-hesary F, Akbari H, Bahadori M, Behnam B. Targeted Anti-Mitochondrial Therapy: The Future of Oncology. Genes 2022;13:1728. [DOI: 10.3390/genes13101728] [Reference Citation Analysis]
|
| 20 |
Chu M, Zheng K, Li X, Luo Z, Yang X, Wei C, Andreucci E. Comprehensive Analysis of the Role of SLC2A3 on Prognosis and Immune Infiltration in Head and Neck Squamous Cell Carcinoma. Analytical Cellular Pathology 2022;2022:1-18. [DOI: 10.1155/2022/2371057] [Reference Citation Analysis]
|
| 21 |
Rao X, Zhang C, Luo H, Zhang J, Zhuang Z, Liang Z, Wu X. Targeting Gastric Cancer Stem Cells to Enhance Treatment Response. Cells 2022;11:2828. [PMID: 36139403 DOI: 10.3390/cells11182828] [Reference Citation Analysis]
|
| 22 |
Samanta D, Gilkes DM, Xiang L, Chaturvedi P, Semenza GL. Enrichment of breast cancer stem cells following cytotoxic chemotherapy is mediated by hypoxia-inducible factors.. [DOI: 10.1101/2022.06.27.497729] [Reference Citation Analysis]
|
| 23 |
Yang Y, Qian DZ, Rey S, Liu JO, Semenza GL. Daily administration of low-dose daunorubicin or doxorubicin inhibits hypoxia-inducible factor 1 and tumor vascularization.. [DOI: 10.1101/2022.06.15.492526] [Reference Citation Analysis]
|
